Programs

Scientific Presentations

09.09.24 | WCLC | Presentation

FURTHER (FURMO-002): A Global, Randomized Study of Firmonertinib at Two Dose Levels in TKI-Naïve, Advanced NSCLC with EGFR PACC Mutations
04.09.24 | AACR | Poster

FURVENT: Global, Phase 3 Trial Testing Furmonertinib versus Chemotherapy as First-Line Treatment for Advanced NSCLC with EGFR Exon 20 Insertion Mutations
04.08.24 | AACR | Poster

Furmonertinib is a highly brain-penetrant EGFR inhibitor broadly active against uncommon EGFR mutations, including PACC and exon 20 insertions
04.08.24 | AACR | Poster

FURTHER (FURMO-002): Global Study to Evaluate Furmonertinib in Patients with EGFR Mutant NSCLC Including Uncommon EGFR Mutations
09.10.23 | WCLC | Presentation

FAVOUR: A phase 1b study of furmonertinib, an oral. Brain penetrant, selective EGFR inhibitor, in patients with advanced NSCLC with EGFR Exon 20 insertions.
09.09.22 | NACLC | Poster

Furmonertinib is an oral, irreversible, highly brain-penetrant Pan EGFR Mutant Inhibitor with activity against classical and atypical EGFR Mutations.
03.08.22 | ELCC | Presentation

FURLONG: Furmonertinib versus gefitinib in treatment-naïve EGFR mutated non-small cell lung cancer: a randomized, double-blind, multi-center, phase III study.
09.16.21 | ESMO | Poster

Preclinical and Preliminary Clinical Investigations of Furmonertinib in NSCLC with EGFR exon 20 insertions (20ins).